Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2021 → 2022: -27.58%
Price change 2022 → 2023: -20.52%
Price change 2023 → 2024: 174.97%
Price change 2024 → 2025: 19.74%
Price change 2025 → 2026: -38.80%
Price change 2026 (year to date): -36.26%
Financial growth
Revenue CAGR (7 years): N/A
Earnings CAGR (7 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.13
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -5.19
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 31.19% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="VERA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Vera Therapeutics, Inc. | – | 0.13 | – | 🔒 |
| Vir Biotechnology, Inc. | – | 0.24 | +115.2 % | – |
| Addus HomeCare Corporation | 18.6 | 0.19 | +11.7 % | ★ 4/5 |
| Fleury S.A. | 16.3 | 1.05 | +16.2 % | – |
| Emeis | – | 6.11 | +11.4 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Accounts and financial health
Balance sheet and cash flow published by Vera Therapeutics, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 79.7 m | 115 m | 161 m | 641 m | 715 m |
| Total Debt | 4.9 m | 31.3 m | 53.7 m | 54.6 m | 77.3 m |
| Net Debt | -74.8 m | -12.2 m | 8.0 m | -38.0 m | -277 m |
| Equity | 69.6 m | 76.9 m | 102 m | 577 m | 605 m |
| Total assets | 83.7 m | 131 m | 176 m | 656 m | 735 m |
| Operating cash flow | -23.7 m | -67.6 m | -92.2 m | -135 m | -241 m |
| Investments (capex) | 0 | 62,000 | 63,000 | 972,000 | 630,000 |
| Free cash-flow | -23.7 m | -67.7 m | -92.2 m | -136 m | -242 m |
| Share buybacks | 0 | 0 | 0 | 13,000 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.
Analyst consensus and forecasts
What the financial analysts covering Vera Therapeutics, Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Average target over the last 3 months: 54.00 USD (4 targets).
Track record against expectations: reported EPS above consensus 3 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Vera Therapeutics, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 05/11/2026 | -1.30 | -1.62 | n/a |
| 10/08/2026 | -1.52 | -1.58 | n/a |
| 07/05/2026 | -1.69 | -1.33 | n/a |
| 26/02/2026 | -1.39 | -1.34 | n/a |
| 05/11/2025 | -1.26 | -1.20 | n/a |
| 05/08/2025 | -1.20 | -0.82 | n/a |
Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Vera Therapeutics, Inc.
Large funds tracked
| Fund | Shares | Value (USD) | Weight in the fund | Change | Quarter |
|---|---|---|---|---|---|
| State Street | 8.3 m | 356 m | 0.0 % | +146.7 % | 2026Q2 |
| BlackRock | 5.7 m | 247 m | 0.0 % | +13.0 % | 2026Q2 |
| Vanguard Group | 3.6 m | 181 m | 0.0 % | +11.9 % | 2025Q4 |
| T. Rowe Price | 4.0 m | 172 m | 0.0 % | -12.3 % | 2026Q2 |
| Morgan Stanley | 2.8 m | 120 m | 0.0 % | +659.2 % | 2026Q2 |
| Fidelity | 2.8 m | 119 m | 0.0 % | +3.6 % | 2026Q2 |
| Geode Capital Management | 1.7 m | 72.6 m | 0.0 % | +7.8 % | 2026Q2 |
| Goldman Sachs | 1.4 m | 59.3 m | 0.0 % | +21.8 % | 2026Q2 |
Latest insider transactions
| Date | Person | Side | Amount |
|---|---|---|---|
| 15/09/2026 | Fordyce Marshall | sale | 684,500 USD |
| 02/09/2026 | Fordyce Marshall | sale | 649,642 USD |
| 07/07/2026 | Fordyce Marshall | sale | 40,776 USD |
| 07/07/2026 | Fordyce Marshall | sale | 1.4 m USD |
| 07/07/2026 | Fordyce Marshall | sale | 450,007 USD |
| 07/07/2026 | Fordyce Marshall | sale | 95,908 USD |
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Vera Therapeutics, Inc.
What is the Vera Therapeutics, Inc. share price?
Latest recorded price: 28.10 USD on 13/11/2026, for a market cap of 2.0 bn USD.
What do analysts say about Vera Therapeutics, Inc.?
Out of 14 analysts: 13 buy or strong buy, 1 hold, 0 sell or strong sell. Average price target: 54.00 USD, i.e. +92.2 % from the share price.
Is Vera Therapeutics, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US92337R1014).
How many employees does Vera Therapeutics, Inc. have?
152 full-time employees according to the latest published profile.
Who runs Vera Therapeutics, Inc.?
Marshall W. Fordyce is the company's chief executive.
Which large funds own Vera Therapeutics, Inc.?
As of 2026Q2, among the large funds tracked: State Street, BlackRock, Vanguard Group, T. Rowe Price, Morgan Stanley.